Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approache...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cell Death Dis
Main Authors: Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, Cervello, Melchiorre
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833482/
https://ncbi.nlm.nih.gov/pubmed/29348495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0195-0
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍